ELAB icon

Elevai Labs

2.29 USD
-0.05
2.14%
At close Apr 30, 4:00 PM EDT
After hours
2.28
-0.01
0.44%
1 day
-2.14%
5 days
-21.84%
1 month
-50.54%
3 months
-80.76%
6 months
-99.99%
Year to date
-86.81%
1 year
-100.00%
5 years
-100.00%
10 years
-100.00%
 

About: PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.

Employees: 3

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

12.02% less ownership

Funds ownership: 13.23% [Q3] → 1.21% (-12.02%) [Q4]

50% less funds holding

Funds holding: 8 [Q3] → 4 (-4) [Q4]

63% less capital invested

Capital invested by funds: $228K [Q3] → $85.5K (-$143K) [Q4]

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for ELAB.

Financial journalist opinion

Based on 4 articles about ELAB published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health
NEWPORT BEACH, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the filing of four novel patent applications for its two candidates EL-22 and EL-32.
RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health
Neutral
GlobeNewsWire
2 days ago
Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial
Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Pha
Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial
Neutral
GlobeNewsWire
2 weeks ago
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company
NEWPORT BEACH, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: PMGC) (the “Company,” “PMGC,” “we,” or “us”), a diversified public holding company, is pleased to announce the signing of a non-binding Letter of Intent (“LOI”) to acquire a U.S.-based, cash-flow positive information technology (“IT”) custom packaging company.
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company
Neutral
GlobeNewsWire
3 weeks ago
Nestpoint Group Fuels Univest Securities, LLC's Ascent to Investment Banking Powerhouse in Trump's Economic Golden Age
New York, New York, April 07, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), New York's premier boutique investment bank, is proud to announce a strategic investment from Nestpoint Group (“Nestpoint”), a leading firm in government affairs, finance, and private equity based in Dallas and Washington, D.C. This powerhouse partnership positions Univest to rise as a global investment banking leader, harnessing unparalleled opportunities for economic expansion under the Trump administration's bold vision for American prosperity.
Nestpoint Group Fuels Univest Securities, LLC's Ascent to Investment Banking Powerhouse in Trump's Economic Golden Age
Neutral
GlobeNewsWire
1 month ago
PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K
NEWPORT BEACH, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has filed its Annual Report on Form 10-K (“Annual Report”) for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (“SEC”).
PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K
Neutral
GlobeNewsWire
1 month ago
NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market
The U.S. animal health market was valued at USD 12.65 billion in 2024 and is expected to grow at a CAGR of 7.97% from 2025 to 2030. This growth is believed to be a consequence of rising innovations surrounding companion animal pharmaceuticals, increasing millennial pet adoption rates, growing livestock populations and production in developing countries, and increasing meat or milk consumption rates, coupled with rising concerns about food-borne diseases.
NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market
Neutral
GlobeNewsWire
1 month ago
Univest Securities, LLC Announces Closing of $1.48 Million Registered Direct Offering for its Client PMGC Holdings Inc. (NASDAQ: ELAB)
New York, New York, March 24, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the “Offering”) for its client PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company”), a diversified holding company.
Univest Securities, LLC Announces Closing of $1.48 Million Registered Direct Offering for its Client PMGC Holdings Inc. (NASDAQ: ELAB)
Neutral
GlobeNewsWire
1 month ago
PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules
NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company, today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 294,450 of the Company's common stock, par value $0.0001 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $5.04 per share in a registered direct offering priced at-the-market under Nasdaq.
PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules
Neutral
GlobeNewsWire
1 month ago
PMGC Holdings Announces Share Repurchases from Existing Shareholders
NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has repurchased shares from certain existing shareholders who contacted the Company directly.
PMGC Holdings Announces Share Repurchases from Existing Shareholders
Neutral
GlobeNewsWire
2 months ago
PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group
NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC,” “our,” or “we”) (Nasdaq: ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's (“TCA”) Orange County network for 2025.
PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group
Charts implemented using Lightweight Charts™